Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Inflammation Biology

Background:

• Atherosclerosis and cardiovascular disease (CVD) are significantly driven by low-density lipoprotein cholesterol (LDL-C) and low-grade arterial inflammation.
• Understanding the interplay between lipid levels and inflammatory processes is crucial for effective CVD prevention strategies.

Purpose of the Study:

• To evaluate the comparative effectiveness of reducing LDL-C versus arterial inflammation, or both, in mitigating cardiovascular events.
• To provide insights into optimal therapeutic approaches for managing atherosclerosis and reducing CVD risk.

Main Methods:

• A narrative review of key clinical trials, including statin trials (4S, GREACE, TNT, JUPITER) and trials investigating targeted anti-inflammatory agents (ARMYDA, CANTOS).
• Analysis of study outcomes based on changes in LDL-C levels, inflammatory markers, and subsequent cardiovascular event rates.

Main Results:

• Statin trials primarily demonstrated benefit through LDL-C reduction, while some showed combined benefits with inflammation reduction.
• Studies targeting only inflammation (e.g., canakinumab) showed benefits independent of lipid changes, but with limitations.
• Combined approaches targeting both LDL-C and inflammation yielded significant benefits in certain trials.

Conclusions:

• Both LDL-C and inflammation reduction are independently and synergistically beneficial in reducing cardiovascular disease risk.
• While targeted anti-inflammatory drugs show promise, their high cost and potential side effects limit widespread clinical application.
• Potent statins possessing anti-inflammatory properties represent a practical and effective therapeutic choice for the majority of patients requiring lipid-lowering and CVD risk reduction.